Seed funding at Waypoint Bio supports drug discovery using in vivo spatial pooled screening technology

July 1, 2024

Waypoint Bio has raised $14.5 million in seed funding to support its work pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology.

BioWorld Science CAR T Cancer Cell therapy Immuno-oncology Seed

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 2, 2025.

Medtronic, Recor commence hostilities over RDN patents

BioWorld MedTech

The renal denervation patent wars are now in full swing, with Medtronic plc and Recor Medical LLC landing the first blow in this chapter of the med tech patent...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...